Myroslava K. Romach
MSc, MD, FRCPC
Senior Vice President, 
Research & Medical Affairs

Dr. Myroslava K. Romach

Dr. Romach is Senior Vice President, Research & Medical Affairs of DecisionLine Clinical Research Corporation. A key opinion leader in CNS Research, Dr. Romach has collaborated on numerous clinical trials for the development of anxiolytics, hypnotics, analgesics, antidepressants and medications for alcohol and drug dependence, and smoking cessation. Dr. Romach manages DecisionLine’s Research Consulting unit– a department that assists sponsors plan and design studies, beginning with reviewing preclinical data, writing protocols and statistical analysis plans, managing and analyzing study data, writing final reports and ending with advice on market placement of a new product.

Dr. Romach is a graduate of the University of Toronto (B.Sc. [Honours] 1976; MSc [Pharmacology] 1979; MD 1984). She is a certified specialist in Psychiatry of the Royal College of Physicians and Surgeons of Canada (FRCPC 1989).
Her current appointments include: Associate Professor of Psychiatry at the University of Toronto and Staff psychiatrist at Mt. Sinai Hospital, Toronto, Canada. She is also a Member of the University Industry CIHR Peer Review Committee.

Dr. Romach’s research interests are in anxiety, depression and substance dependence disorders in women, and self-regulation of mood by medications such as anxiolytics and analgesics. She has conducted numerous psychopharmacologic studies and clinical trials. She is active in post-graduate medical education, and is a highly effective communicator concerning optimal medication use in women. Her research projects involve examining pregnancy related depression. She has published over 45 research papers and chapters and presented over 60 invited papers at Canadian and International conferences including the American Psychiatric Association and American College of Neuropsychopharmacology.

John Oldenhof 
MSc, PhD
Director, Clinical Pharmacology

Dr. John Oldenhof

Dr. Oldenhof is the Manager of DecisionLine’s Clinical Pharmacology group and is responsible for providing advanced scientific input on project teams. Under his supervision, the Clinical Pharmacology group scientific consulting, designs and writes concept protocols, full protocols and informed consent forms as well as preparing integrated clinical reports, abstracts and manuscripts.

Dr. Oldenhof received his PhD in Pharmacology from the University of Toronto in 1999. His doctoral work in molecular neurobiology demonstrated the interaction of the third intracellular loop of the dopamine D4 receptor with specific intracellular SH3 containing proteins. Dr. Oldenhof’s Master’s research was in behavioural pharmacology using animal models to investigate the rewarding properties of ethanol and its metabolites. Dr. Oldenhof gained extensive pre-clinical, clinical and regulatory experience while working for Hemosol Inc, a biotechnology company developing hemoglobin-based oxygen carriers (HBOCs). As medical scientist he was part of the team that developed phase II and III protocols and analyzed the results of these studies. He also managed pre-clinical research with several leading academic laboratories. This research involved advanced imaging techniques to demonstrate the oxygen carrying capabilities of HBOCs in capillaries and animal models of hemodilution to investigate the effect of HBOCs on critical oxygen delivery.

Dr. Oldenhof is a highly regarded scientist who has more than 20 published research papers and abstracts.

Kerri Schoedel 
PhD
Senior Scientist

Dr. Kerri Schoedel 

As part of the Research Consulting group, Dr. Schoedel is responsible for study design, and scientific support for complex scientific and clinical projects. Dr. Schoedel’s primary research interest is abuse liability, with a secondary focus on clinical epidemiology/surveillance, and pharmacokinetics. She has been involved in the design, scientific development, and/or clinical implementation/project management of numerous projects including Phase I clinical studies (abuse liability, safety/tolerability, pharmacokinetics, and/or neurocognitive endpoints), expert opinion reports, abuse surveillance/risk minimization plans, regulatory applications, manuscripts, presentations, and literature reviews.

Dr. Schoedel received her Honours B.Sc. in Biomedical Sciences at the University of Guelph (degree conferred With Distinction), and completed her Ph.D. in Pharmacology at the University of Toronto, with specialization in nicotine addiction, drug metabolism, and pharmacogenetics. Dr. Schoedel’s doctoral studies included the characterization of variation in nicotine-metabolizing enzymes and nicotine metabolism and the assessment of the impact of this variation on smoking risk/behaviour in humans. In the course of her graduate studies, Dr. Schoedel received additional training in clinical, behavioural, and experimental pharmacology, pharmacokinetics, drug development, biostatistics, and research methodology.

Dr. Schoedel is a highly regarded scientist who has been involved in over 30 research and review articles, book chapters, and national/international scientific presentations. She has also received numerous academic awards, including national and provincial scholarships (Canadian Institute of Health Research, Natural Sciences & Engineering Research Council of Canada, Ontario Graduate Scholarship, Strategic Training Program in Tobacco Research), institutional awards (University of Toronto Amar Sen Memorial Award for Excellence in Academic Achievement, Top-up Award, Centre for Addiction and Mental Health doctoral award, University of Guelph Alma Mater and Dean’s Scholarship), and publication/presentation awards.

Marta Sokolowska
PhD
Research Scientist

Dr. Marta Sokolowska 

As part of the Research Consulting group, Dr. Sokolowska is responsible for study design and scientific support for complex scientific and clinical projects. Her research interests include examination of drug formulations, alcohol and drug interactions and abuse liability. She has been involved in the design, scientific development, and/or clinical implementation/project management of numerous projects including Phase I clinical studies, expert opinion reports, literature reviews, presentations and regulatory applications.
Dr. Sokolowska’s previous research interests included classical conditioning approach to opiate tolerance and withdrawal as well as affective disorders induced neurocognitive dysfunctions. She received her PhD in Psychology from McMaster University, for examination of contribution of pharmacological cues to morphine tolerance and withdrawal. In addition, she completed a Post-Doctoral Fellowship at the Department of Psychiatry and Behavioural Neuroscience at McMaster University specializing in evaluation of the affective disorder-induced memory impairments.

Dr. Sokolowska is a highly regarded scientist who has published numerous research and review articles, book chapters as well as seminar and poster presentations.